RISO PHARMA TECH AND TABUK PHARMACEUTICAL MANUFACTURING COMPANY (SAUDI ARABIA) www.tpmc.com.sa ENTER INTO CONSULTING AGREEMENT
Riso Pharma Tech (RISO) and Tabuk Pharmaceutical Manufacturing Company (TABUK) today signed an agreement in which RISO will act as TUBUK’s licensing consultant and work with TABUK to in-license products for the therapeutic areas served by TABUK.
Under this agreement RISO will collaborate closely with TABUK’s Business Development team to identify and secure late clinical stage and marketed products which fit TABUK’s vision of growth for the future. TABUK is currently the second largest Saudi Arabian pharmaceutical company, with sales in the region in excess of US$100 MM.
September 17, 2008
Riso Pharma has entered an agreement with Omega Laboratory of Montreal, Canada to custom manufacture a line of Oncolgy products for the Middles East region . Riso hopes to have Oncology product line into the market by early 2009.
July 8, 2008
Dr. P. Daniel Bagi, Managing Director of RisoPharma Tech has been invited to be a panel speaker at the LESI International Conference on May 6, to speak about his experiences in the pharmaceutical licensing arena in the Middle East. There will also be a Question & Answer session at the end of the workshop.
April 22, 2008
Riso PharmaTech Inc. will be attending the LES International Conference – Licensing Without Borders in Chicago on May 4-7. This conference gathers the Business Development and Licensing professionals from various disciplines, including the Pharmaceutical Sector. Riso’s goals are to meet biotech and pharmaceutical companies with products available for licensing into our territories of interest: Middle East and Latin America.
April 5, 2008
Dr. P. Daniel Bagi, Managing Director of RisoPharma Tech has been invited to be a panel speaker at the LESI International Conference on May 6, to speak about his experiences in the pharmaceutical licensing arena in the Middle East. There will also be a Question & Answer session at the end of the workshop
March 20, 2008
Pharmaceutical companies need not be apprehensive when considering doing business in certain territories where there may be political concerns. Riso Pharma Tech has helped numerous US pharmaceutical and Biotech companies obtain the necessary permits form the US government (OFAC license), which grants authorization for US-based manufacturing companies to ship their products to countries like Iran.
March 14, 2008
Pharmaceutical companies need not be apprehensive when considering doing business in certain territories where there may be political concerns. Riso Pharma Tech has helped numerous US pharmaceutical and Biotech companies obtain the necessary permits form the US government (OFAC license), which grants authorization for US-based manufacturing companies to ship their products to countries like Iran
Riso Pharma Tech is a Canadian-based specialty pharmaceutical company focused on in-licensing late-stage and approved molecules for marketing and sales in Canada, certain European Union countries, Latin America, and the Middle East.
From large multi-national pharmaceutical companies to small biotechs, Riso's license deals have yielded successful product launches in its territories. Five regional offices and over 360 employees worldwide enable Riso to extend the reach of our partner companies' products.
With an extensive track record of greater than 10+ years marketing and sales success in its territories, and thanks to Riso's financial strength, Riso is aggressively pursuing new in-licensing opportunities across several therapeutic areas: oncology, supportive care, neurology, endocrinology and women's health.
